Drug Trial Radar · NCT00998283
Assess the Safety, Tolerability, and Pharmacokinetic (PK) Characteristics of HM10460A (HNK460) in Healthy Adult Korean Subjects
Last checked: Nov 20, 2026Latest source record: Feb 7, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Oct 2009
Primary completion
Sep 2010
Study completion Sep 2010
Sponsor
- Lead sponsor
- Hanmi Pharmaceutical Company LimitedIndustry
- Sponsor type
- Industry
- First posted
- Oct 20, 2009
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
* Study Design * Randomized, Double-blind, Placebo-controlled, escalating single-dose design. * Five ascending dose cohorts. * In each cohort, subjects will be randomized to receive a single dose of HM10460A or placebo (negative control) * Objectives * The primary objective of the study is to assess the safety and tolerability of single escalating subcutaneous doses of HM10460A in healthy adult Korean Subjects
Conditions
- Healthy
Interventions
HM10460A 5μg/kgDrug
Subcutaneously administrate at 0 hour on Day 1
HM10460A 15μg/kgDrug
Subcutaneously administrate at 0 hour on Day 1
HM10460A 45μg/kgDrug
Subcutaneously administrate at 0 hour on Day 1
HM10460A 135μg/kgDrug
Subcutaneously administrate at 0 hour on Day 1
HM10460A 350μg/kgDrug
Subcutaneously administrate at 0 hour on Day 1
PlaceboDrug
Subcutaneously administrate at 0 hour on Day 1
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety data, including physical examinations (to include injection site reactions and splenic evaluations), laboratory evaluations, ECGs, vital signs, and adverse effects (AEs)Time frame: Time point of collection, where appropriate
- Samples for immunogenicityTime frame: Time point of collection, where appropriate
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.